Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration

Jeremy B Wingard1 Wheaton Eye Clinic, Wheaton, IL60187, USACorrespondence[email protected]

Darcie AP Delzell2 Mathematics and Computer Science Department, Wheaton College, Wheaton, IL, 60187, USA

Nathan V Houlihan2 Mathematics and Computer Science Department, Wheaton College, Wheaton, IL, 60187, USA

Jonathan Lin2 Mathematics and Computer Science Department, Wheaton College, Wheaton, IL, 60187, USA

Jon P Gieser1 Wheaton Eye Clinic, Wheaton, IL60187, USA

Figures & data

Table 1 Demographic Characteristics of Patients by Injected Medication

Download CSV Display Table

Table 2 Injection Patterns by Lens and Event Status

Download CSV Display Table

Figure 1 Histogram showing time from first intravitreal anti-vascular endothelial growth factor injection to development of glaucoma or sustained ocular hypertension, with each column representing 2 months. Incidence is distributed over 4+ years of follow-up, with 8 subjects developing disease before 1 year, 22 from years 1–3, and an additional 10 after 3 years from the first injection.

Table 3 Logistic Regression Results Predicting the Probability of Glaucoma or Sustained Ocular Hypertension

Download CSV Display Table

Figure 2 Using the results of the logistic regression (coefficients from the reduced model in ), the predicted probability of disease is graphed against the highest injection rate over any 6-month period. This relationship is displayed distinctly for the four combinations of sex and lens status.

Figure 2 Using the results of the logistic regression (coefficients from the reduced model in Table 3), the predicted probability of disease is graphed against the highest injection rate over any 6-month period. This relationship is displayed distinctly for the four combinations of sex and lens status.

Table 4 Odds Ratios for Firth’s Logistic Regression (See )

Download CSV Display Table

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration

Table 1 Demographic Characteristics of Patients by Injected Medication

Table 2 Injection Patterns by Lens and Event Status

Table 3 Logistic Regression Results Predicting the Probability of Glaucoma or Sustained Ocular Hypertension

Table 4 Odds Ratios for Firth’s Logistic Regression (See )

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration

Figures & data

Table 1 Demographic Characteristics of Patients by Injected Medication

Table 2 Injection Patterns by Lens and Event Status

Table 3 Logistic Regression Results Predicting the Probability of Glaucoma or Sustained Ocular Hypertension

Table 4 Odds Ratios for Firth’s Logistic Regression (See Table 3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 4 Odds Ratios for Firth’s Logistic Regression (See )